China SXT Pharmaceuticals Issues Shares to Raise $10 Million

China SXT Pharmaceuticals' stock is down 6.49% in pre-market trading, hitting a 52-week low.

The company has entered into an agreement to issue 66.67 million Class A ordinary shares at $0.15 each, expecting to raise approximately $10 million to enhance liquidity for future growth. This financing is set to close around January 12, 2026, subject to customary closing conditions, which will provide timely access to funds for operational needs. The offering is made under an F-3 registration statement that became effective on December 1, 2025, ensuring compliance and transparency for investors.

This capital raise is crucial for China SXT Pharmaceuticals as it seeks to strengthen its financial position and support its growth initiatives, especially in the competitive landscape of traditional Chinese medicine.